预防性颅脑照射治疗小细胞肺癌：单机构经验。
Prophylactic cranial irradiation in small cell lung cancer: a single institution experience.
机构信息
Beaumont Hospital, Beaumont Rd, P.O. Box 1297, Dublin 2, Ireland,
出版信息
Ir J Med Sci. 2014 Mar;183(1):129-32. doi: 10.1007/s11845-013-0977-z. Epub 2013 Jun 13.
BACKGROUND
Prophylactic cranial irradiation (PCI) is used to prevent the development of brain metastases in small cell lung carcinoma. PCI confers an overall survival (OS) benefit in both limited and extensive stage disease.
AIMS
We analyze the incidence of symptomatic brain metastases, progression-free survival (PFS) and OS in a cohort of patients who received PCI, in a 5-year period.
METHODS
A retrospective review of all patients who had received PCI between 2006 and 2011 at the Whitfield Clinic was completed. Patient- and disease-related characteristics, the number of patients who developed brain metastases, PFS and OS data were collected.
RESULTS
24 patients were identified. 14 (58.3 %) patients were male, 10 (41.7 %) were female, with a mean age of 62.5 years (range 31-78). All patients were smokers. 12 (50 %) patients had limited stage small cell lung cancer (SCLC), 12 (50 %) had extensive stage disease. 2 (8.2 %) patients developed brain metastases post PCI (p = 0.478.) The median PFS for limited stage SCLC was 13 months (range 3-20) and 10 months (range 5-18) for extensive stage SCLC. Median OS was 15 months (range 4-29) in limited stage SCLC, and 11 months (range 5-29) in extensive stage SCLC.
CONCLUSIONS
Our study demonstrated a low incidence of symptomatic brain metastases and favourable median PFS and OS in the patients that received PCI, when compared to published phase III data.
背景
预防性颅脑照射（PCI）用于预防小细胞肺癌脑转移的发生。PCI 在局限期和广泛期疾病中均能带来总生存（OS）获益。
目的
我们分析了一组接受 PCI 的患者在 5 年内发生症状性脑转移、无进展生存（PFS）和 OS 的情况。
方法
对 2006 年至 2011 年期间在 Whitfield 诊所接受 PCI 的所有患者进行回顾性分析。收集患者和疾病相关特征、发生脑转移的患者数量、PFS 和 OS 数据。
结果
共确定 24 例患者。14 例（58.3%）为男性，10 例（41.7%）为女性，平均年龄为 62.5 岁（范围 31-78 岁）。所有患者均为吸烟者。12 例（50%）为局限期小细胞肺癌（SCLC）患者，12 例（50%）为广泛期疾病患者。2 例（8.2%）患者在接受 PCI 后发生脑转移（p=0.478）。局限期 SCLC 的中位 PFS 为 13 个月（范围 3-20），广泛期 SCLC 为 10 个月（范围 5-18）。局限期 SCLC 的中位 OS 为 15 个月（范围 4-29），广泛期 SCLC 为 11 个月（范围 5-29）。
结论
与已发表的 III 期数据相比，我们的研究表明，接受 PCI 的患者发生症状性脑转移的发生率较低，且中位 PFS 和 OS 较好。
Zotero 插件